News

The ticking clock of metabolic disease

Mitchell Lazar studies the transcription factors linking circadian disruption to obesity and diabetes.
Written bySarah Anderson, PhD
| 6 min read
An outline of the human body filled with many clocks.

Mismatch between the body’s internal clock and the time of day may contribute to higher rates of metabolic disease in night shift workers.

credit: istock/wildpixel

Mitchell Lazar planned on becoming a chemist. But when his chemistry studies landed him in a lecture on the brain, he became fascinated by how neurotransmitters and drugs could influence sophisticated brain functions. “As somebody interested in chemistry and also with some family history of mental illness, I thought this would be a great way to understand the biochemical basis of behavior,” Lazar said. He pivoted to pursue an MD-PhD to study neurochemistry and went on to train as an endocrinologist, conduct research on thyroid hormone receptors, and eventually become a leading expert on the molecular mechanisms underlying metabolic disease.

Mitchell Lazar investigates how circadian rhythms influence transcription factors and metabolic genes.
credit: Mitchell Lazar/Perelman School of Medicine at the University of Pennsylvania

In many ways, his career path parallels the metabolic mechanisms he studies, where unforeseen external influences trigger cascades with far reaching and unexpected ripple effects. Now the director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania, Lazar investigates the transcriptional regulation of metabolism and how environmental factors such as circadian disruption can throw it out of balance, leading to obesity and diabetes. By examining the effects of genetic and environmental changes on metabolic physiology, he maps the complex interactions between circadian rhythms, transcription factors, and metabolism. His research provides insights that help identify new drug targets, drug time courses, and biomarkers to treat metabolic disease.

How would you characterize the roles of genetic and environmental factors in driving metabolic disease?

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Sarah Anderson, PhD

    Sarah Anderson joined Drug Discovery News as an assistant editor in 2022. She earned her PhD in chemistry and master’s degree in science journalism from Northwestern University. She served as managing editor of the Illinois Science Council’s “Science Unsealed” blog and has written for Discover MagazineAstronomy MagazineChicago Health Magazine, and others. She enjoys reading at the beach, listening to Taylor Swift, and cuddling her cat, Augustus.

    View Full Profile

Here are some related topics that may interest you:

Published In

February 2023 Front Cover
Volume 19 - Issue 2 | February 2023

February 2023

February 2023 Issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue